MEDICINE FOR TREATING INFLUENZA OR INFECTIOUS DISEASES

Abstract

The present invention relates to the field of medical care, and it relates to the application of alkaloids and volatile oils contained in plants such as Gastrodia elata, Pinellia ternata, Orange Peel and Uncaria rhynchophylla in the preparation of medicines or health products for treating influenza or infectious diseases caused by viruses or fungi; especially, it relates to new use of the alkaloids and volatile oils contained in raw materials such as Gastrodia elata, Pinellia ternata, Orange Peel, Unearia and other plants in the preparation of drugs or health products for treating influenza or infectious diseases caused by influenza viruses (including HN avian influenza), coronavirus, Ebola virus, AIDS, Aspergillus, Cryptococcus, Mucor, Histoplasma capsulatum, etc.

Claims

1. A medicine for treating influenza or infectious diseases caused by viruses or fungi, characterized in that the medicine is used for treating influenza or infectious diseases caused by influenza viruses, coronaviruses, Ebola virus, AIDS, Aspergillus, Cryptococcus, Mucor, Entomophthora, Histoplasma capsulatum, wherein the active pharmaceutical ingredients of the medicine include total alkaloids and/or total volatile oils extracted from Gastrodia elata, total alkaloids and/or total volatile oils extracted from Pinellia ternata, total alkaloids and/or total volatile oils extracted from Orange Peel, and total alkaloids and/or total volatile oils extracted from Uncaria rhynchophylla, wherein the methods for preparing the medicine include: taking the total alkaloids of Gastrodia elata, the total alkaloids of Pinellia ternata, the total alkaloids of Orange Peel and the total alkaloids of Uncaria rhynchophylla and mixing them in a certain proportion; adding various conventional excipients required to prepare different dosage forms thereto; and preparing pharmaceutically acceptable dosage forms; taking the total volatile oils of Gastrodia elata, the total volatile oils of Pinellia ternata, the total volatile oils of Orange Peel and the total volatile oils of Uncaria rhynchophylla and mixing them in a certain proportion; adding various conventional excipients required to prepare different dosage forms thereto; and preparing pharmaceutically acceptable dosage forms; taking the total alkaloids and total volatile oils of Gastrodia elata, the total alkaloids and total volatile oils of Pinellia ternata, the total alkaloids and total volatile oils of Orange Peel, the total alkaloids and total volatile oils of Uncaria rhynchophylla; mixing the volatile oils in a proportion, then mixing them with the dry alkaloid substances and an appropriate amount of excipients after inclusion with beta-cyclodextrin, and preparing pharmaceutically acceptable dosage forms using conventional methods for preparing medicines.

2. The medicine according to claim 1, characterized in that when the clinical symptoms appear to be upper respiratory tract infection symptoms, the active pharmaceutical ingredients of the medicine can be selectively added with: total alkaloids and/or total volatile oils extracted from Ginger, total alkaloids and/or total volatile oils extracted from Notopterygium incisum, total alkaloids and/or total volatile oils extracted from Saposhnikovia divaricata, total alkaloids and/or total volatile oils extracted from Ligusticum levisticum, total alkaloids and/or total volatile oils extracted from Flos Magnoliae, total alkaloids and/or total volatile oils extracted from Mentha haplocalyx, total alkaloids and/or total volatile oils extracted from Mulberry Leaves, total alkaloids and/or total volatile oils extracted from Chaste Tree Fruits.

3. The medicine according to claim 1, characterized in that when the clinical symptoms appear to be digestive system symptoms, the active pharmaceutical ingredients of the medicine can be selectively added with: total alkaloids and/or total volatile oils extracted from Agastache rugosa, total alkaloids and/or total volatile oils extracted from Atractylodes lancea, total alkaloids and/or total volatile oils extracted from Magnolia officinalis.

4. The medicine according to claim 1, characterized in that when the clinical symptoms appear to be pneumonia symptoms, the active pharmaceutical ingredients of the medicine can be selectively added with: total alkaloids and/or total volatile oils extracted from Rhizoma arisaematis, total alkaloids and/or total volatile oils extracted from Sinapis alba, total alkaloids and/or total volatile oils extracted from Fritillaria cirrhosa, total alkaloids and/or total volatile oils extracted from Trichosanthes kirilowii, total alkaloids and/or total volatile oils extracted from Radix Stemona, and total alkaloids and/or total volatile oils extracted from Semen Lepidii.

5. The medicine according to claim 1, characterized in that when the clinical symptoms appear to be general symptoms, the active pharmaceutical ingredients of the medicine can be selectively added with: total alkaloids and/or total volatile oils extracted from Radix angelicae pubescentis, total alkaloids and/or total volatile oils extracted from Ligusticum wallichii, total alkaloids and/or total volatile oils extracted from Achyranthes bidentata, total alkaloids and/or total volatile oils extracted from Astragalus membranaceus, total alkaloids and/or total volatile oils extracted from Angelica sinensis, total alkaloids and/or total volatile oils extracted from Aconitum carmichaeli, total alkaloids and/or total volatile oils extracted from Herba artemisiae scopariae, total alkaloids and/or total volatile oils extracted from Garlic, total alkaloids and/or total volatile oils extracted from Cirsium setosum, and total alkaloids and/or total volatile oils extracted from Cirsium japonicum.

6. The medicine according to claims 1, characterized in that the methods for preparing the medicine include: taking Gastrodia elata, Pinellia ternata, Orange Peel and Uncaria rhynchophylla as the basic raw materials, selectively adding them with raw materials according to the clinical symptoms, extracting the respective total alkaloids and total volatile oils from the raw materials according to the weight parts of the selected raw materials by using modern conventional extraction methods, mixing the total alkaloids and adding conventional excipients thereto, and preparing pharmaceutically acceptable dosage forms such as tablets or powder injections according to conventional processes for preparing medicines; mixing the respective total volatile oils and adding conventional excipients thereto, and preparing pharmaceutically acceptable dosage forms according to conventional processes for preparing medicines; mixing the volatile oils in a proportion and then mixing them with the dry alkaloid substances and an appropriate amount of excipients after inclusion with beta-cyclodextrin, and preparing pharmaceutically acceptable dosage forms such as tablets, granules using conventional methods for preparing medicines.

7. The medicine according to claim 1, characterized in that the methods for preparing the medicine include: according to the weight parts of the selected raw materials, mixing the total alkaloids and/or total volatile oil extracted from Gastrodia elata, Pinellia ternata, Orange Peel and Uncaria rhynchophylla by using modern conventional extraction methods; mixing the total alkaloids and/or total volatile oils extracted from the raw materials added according to the clinical symptoms, and adding conventional excipients thereto; preparing pharmaceutically acceptable dosage forms according to conventional processes for preparing medicines; and obtaining an A+B combination.

8. The medicine according to claim 1, characterized in that the methods for preparing the medicine include: extracting total alkaloids and/or total volatile oils from the corresponding fresh raw materials and grouping them to prepare medicine, wherein a standard dose of 15 g of the dry product is used for each of the raw materials; the specific groups are as follows: (1) Gastrodia elata, Pinellia ternata, Orange Peel and Uncaria rhynchophylla; (2) Ginger, Notopterygium incisum, Saposhnikovia divaricata, Ligusticum levisticum and Flos Magnoliae; (3) Mentha haplocalyx, Mulberry leaves and Chaste Tree Fruits; (4) Agastache rugosa, Atractylodes lancea, Magnolia officinalis, Garlic and/or Herba artemisiae scopariae; (5) Rhizoma arisaematis, Sinapis alba and Radix Stemona; (6) Fritillaria cirrhosa, Trichosanthes kirilowii and Semen Lepidii; (7) Radix angelicae pubescentis, Achyranthes bidentata, Aconitum carmichaeli; (8) Astragalus membranaceus, Angelica sinensis and Ligusticum wallichii; (9) Cirsium setosum and Cirsium japonicum; wherein the extracted total alkaloids in small groups are used to prepare pharmaceutically acceptable dosage forms; the extracted total volatile oils in small groups are used to prepare pharmaceutically acceptable dosage forms; and the extracted total alkaloids and total volatile oils in small groups are used to prepare pharmaceutically acceptable dosage forms.

9. The medicine according to claim 1, characterized in that the scope of application of the medicine to treat influenza or infectious diseases caused by influenza viruses or HN avian influenza virus, coronaviruses or coronavirus 2019-COVID or MERS virus or SARS coronavirus, Ebola virus, AIDS, Aspergillus, Cryptococcus, Mucor, Entomophthora and Histoplasma capsulatum includes applications in medical drugs and health products.

Description

Specific Implementation Mode

Example 1

[0066] The medicine for treating influenza caused by an influenza virus (including HN avian influenza) or Histoplasma capsulatum or Aspergillus flavus according to this example. The formulation is optimized according to the clinical manifestations of influenza.

[0067] 1. Typical influenza, also known as simple flu. The clinical manifestations are: sudden chills, fever, headache, eye pain, muscle soreness, obvious fatigue, dry throat pain, burning sensation under sternum (from trachea), the upper respiratory tract symptoms such as occasional nasal congestion, runny nose, sneezing, dry cough, as well as nausea and diarrhea.

[0068] The composition of the active pharmaceutical ingredients (dry product) of this example is as follows: total alkaloids and/or volatile oils extracted from 25 g of Gastrodia elata, total alkaloids and/or volatile oils extracted from 15 g of Pinellia ternata, total alkaloids and/or volatile oils extracted from 10 g of Orange Peel, total alkaloids and/or volatile oils extracted from 25 g of Uncaria rhynchophylla, total alkaloids and/or volatile oils extracted from 10 g of Notopterygium incisura, total alkaloids and/or volatile oils extracted from 15 g of Saposhnikovia divaricata, total alkaloids and/or volatile oils extracted from 15 g of Flos Magnoliae, total alkaloids and/or volatile oils extracted from 20 g of Mentha haplocalyx, total alkaloids and/or volatile oils extracted from 20 g of Mulberry Leaves, total alkaloids and/or volatile oils extracted from 15 g of Ligusticum wallichii, total alkaloids and/or volatile oils extracted from 20 g of Atractylodes lancea.

[0069] 2. Pneumonic influenza, also known as primary influenza virus pneumonia.

[0070] (1) Mild onset such as typical influenza: cough, light grey sticky sputum after 1-2 days, no obvious dyspnea, X-ray examination of the lungs shows inflammatory shadow.

[0071] The composition of the active pharmaceutical ingredients (dry product) of this example is as follows: total alkaloids and/or volatile oils extracted from of 25 g of Gastrodia elata, total alkaloids and/or volatile oils extracted from 25 g of Pinellia ternata, total alkaloids and/or volatile oils extracted from 20 g of Orange Peel, total alkaloids and/or volatile oils extracted from 20 g of Uncaria rhynchophylla, total alkaloids and/or volatile oils extracted from 20 g of Sinapis alba, total alkaloids and/or volatile oils extracted from 30 g of Trichosanthes kirilowii and total alkaloids, and/or volatile oils extracted from 20 g of Atractylodes lancea.

[0072] (2) The onset of severe symptoms is the same as that of typical influenza: the cough worsens sharply after 1-2 days, high fever, exhaustion, severe cough, bloody sputum, secondary shortness of breath and cyanosis. Respiratory and circulatory failure and death often occur within 1-2 weeks.

[0073] The composition of the active pharmaceutical ingredients (dry product) of this example is as follows: total alkaloids and/or volatile oils extracted from 30 g of Gastrodia elata, total alkaloids and/or volatile oils extracted from 25 g of Pinellia ternata, total alkaloids and/or volatile oils extracted from 20 g of Orange Peel, total alkaloids and/or volatile oils extracted from 30 g of Uncaria rhynchophylla, total alkaloids and/or volatile oils extracted from 30 g of Fritillaria cirrhosa, total alkaloids and/or volatile oils extracted from 30 g of Trichosanthes kirilowii, total alkaloids and/or volatile oils extracted from 15 g of Semen Lepidii, total alkaloids and/or volatile oils extracted from 30 g of Garlic, and total alkaloids and/or volatile oils extracted from 20 g of Cirsium setosum.

[0074] When the high fever subsides and respiratory and circulatory failure occurs, the composition of the active pharmaceutical ingredients (dry product) of this example is as follows: total alkaloids and/or volatile oils extracted from 30 g of Gastrodia elata, total alkaloids and/or volatile oils extracted from 30 g of Pinellia temata, total alkaloids and/or volatile oils extracted from 20 g of Orange Peel, total alkaloids and/or volatile oils extracted from 20 g of Uncaria rhynchophylla, total alkaloids and/or volatile oils extracted from 25 g of Rhizoma arisaematis, total alkaloids and/or volatile oils extracted from 20 g of Sinapis alba, total alkaloids and/or volatile oils extracted from 20 g of Radix Stemma, total alkaloids and/or volatile oils extracted from 30 g of Aconitum caunichaeli, total alkaloids and/or volatile oils extracted from 30 g of Astragalus membranaceus, total alkaloids and/or volatile oils extracted from 15 g of Angelica sinensis, total alkaloids and/or volatile oils extracted from 20 g of Ligusticum wallichii, and total alkaloids and/or volatile oils extracted from 20 g of Atractylodes lancea.

[0075] When passing through the critical period and entering the rehabilitation period, the composition of the active pharmaceutical ingredients (dry product) of this example is as follows: total alkaloids and/or volatile oils extracted from 20 g of Gastrodia elata, total alkaloids and/or volatile oils extracted from 20 g of Pinellia ternata, total alkaloids and/or volatile oils extracted from 15 g of Orange Peel, total alkaloids and/or volatile oils extracted from 15 g of Uncaria rhynchophylla, total alkaloids and/or volatile oils extracted from 15 g of Sinapis alba, total alkaloids and/or volatile oils extracted from 20 g of Astragalus membranaceus, total alkaloids and/or volatile oils extracted from 10 g of Angelica sinensis, total alkaloids and/or volatile oils extracted from 10 g of Ligusticum wallichii, and total alkaloids and/or volatile oils extracted. from 15 g of Atractylodes lancea.

Example 2

[0076] This example is used to treat influenza caused by various coronaviruses. Specifically, it is aimed at the formulation of medicine designed for treating novel coronavirus 2019-COVID. The formulation is optimized by referring to the clinical manifestations and traditional Chinese medicine treatment in the “Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia” (Trial Version 5) published in China.

[0077] 1. Medical observation period: the clinical manifestations are fatigue with gastrointestinal discomfort or fatigue with fever.

[0078] The composition of the active pharmaceutical ingredients (dry product) of this example is as follows: total alkaloids and/or volatile oils extracted from 15 g of Gastrodia elata, total alkaloids and/or volatile oils extracted from 15 g of Pinellia ternata, total alkaloids and/or volatile oils extracted from 10 g of Orange Peel, total alkaloids and/or volatile oils extracted from 15 g of Uncaria rhynchophylla.

[0079] 2. Clinical treatment period: (1) the initial clinical manifestations are fever with aversion to cold or apyrexia, dry cough, dry throat, general fatigue, chest tightness, abdominal distension or vomiting, diarrhea, light red tongue, white and greasy tongue coating.

[0080] The composition of the active pharmaceutical ingredients (dry product) of this example is as follows: total alkaloids and/or volatile oils extracted from 20 g of Gastrodia elata, total alkaloids and/or volatile oils extracted from 20 g of Pinellia. ternata, total alkaloids and/or volatile oils extracted from 15 g of Orange Peel, total alkaloids and/or volatile oils extracted from 20 g of Uncaria rhynchophylla, total alkaloids and/or volatile oils extracted from 15 g of Agastache rugosa, total alkaloids and/or volatile oils extracted from 15 g of Atractylodes lancea, total alkaloids and/or volatile oils extracted from 15 g of Ginger, and total alkaloids and/or volatile oils extracted from 10 g of Notopterygium incisum.

[0081] (2) The intermediate clinical manifestations are high fever, cough with less phlegm, or yellow phlegm, abdominal distension and constipation, chest tightness, shortness of breath and panting, asthma, red tongue, yellow and greasy tongue coating.

[0082] The composition of the active pharmaceutical ingredients (dry product) of this example is as follows: total alkaloids and/or volatile oils extracted from 30 g of Gastrodia elata, total alkaloids and/or volatile oils extracted from 20 g of Pinellia ternata, total alkaloids and/or volatile oils extracted from 10 g of Orange Peel, total alkaloids and/or volatile oils extracted from 30 g of Uncaria rhynchophylla, total alkaloids and/or volatile oils extracted from 15 g of Atractylodes lancea, total alkaloids and/or volatile oils extracted from 15 g of Magnolia officinalis, total alkaloids and/or volatile oils extracted from 30 g of Fritillaria cirrhosa, total alkaloids and/or volatile oils extracted from 30 g of Trichosanthes kirilowii, total alkaloids and/or volatile oils extracted from 15 g of Semen Lepidii, and total alkaloids and/or volatile oils extracted from 15 g of Garlic.

[0083] (3) The severe clinical manifestations are dyspnea, asthma, oxygen lack with coma, irritability, sweating cold limbs, dark purple tongue, thick greasy or dry tongue coating.

[0084] The composition of the active pharmaceutical ingredients (dry product) of this example is as follows: total alkaloids and/or volatile oils extracted from 35 g of Gastrodia elata, total alkaloids and/or volatile oils extracted from 35 g of Pinellia ternata, total alkaloids and/or volatile oils extracted from 30 g of Orange Peel, total alkaloids and/or volatile oils extracted from 20 g of Uncaria rhynchophylla, total alkaloids and/or volatile oils extracted from 25 g of Rhizoma arisaematis, total alkaloids and/or volatile oils extracted from 20 g of Sinapis alba, total alkaloids and/or volatile oils extracted from 20 g of Radix Stemma, total alkaloids and/or volatile oils extracted from 20 g of Aconitum carmichaeli, total alkaloids and/or volatile oils extracted from 30 g of Astragalus membranaceus, total alkaloids and/or volatile oils extracted from 15 g of Angelica sinensis, total alkaloids and/or volatile oils extracted from 20 g of Ligusticum wallichii, total alkaloids and/or volatile oils extracted from 15 g of Achyranthes bidentata, and total alkaloids and/or volatile oils extracted from 15 g of Herba artemisiae scopariae.

[0085] (4) The clinical manifestations in the recovery period are short breath, fatigue, loss of appetite, vomiting, abdominal distension, loose stool, white and greasy tongue coating.

[0086] The composition of the active pharmaceutical ingredients (dry product) of this example is as follows: total alkaloids and/or volatile oils extracted from 15 g of Gastrodia elata, total alkaloids and/or volatile oils extracted from 15 g of Pinellia ternata, total alkaloids and/or volatile oils extracted from 15 g of Orange Peel, total alkaloids and/or volatile oils extracted from 10 g of Uncaria rhynchophylla, total alkaloids and/or volatile oils extracted from 15 g of Atractylodes lancea, total alkaloids and/or volatile oils extracted from 15 g of Magnolia officinalis, total alkaloids and/or volatile oils extracted from 30 g of Astragalus membranaceus, total alkaloids and/or volatile oils extracted from 15 g of Angelica sinensis, and total alkaloids and/or volatile oils extracted from 15 g of Radix angelicae pubescentis.

[0087] Technical effect analysis: during the treatment of pneumonia caused by Wuhan novel coronavirus in 2020, the treatment of patients by using the combination of traditional Chinese medicine and Western medicine in the initial and intermediate periods was obviously more effective compared to the treatment of patients by using only Western medicine. The Chinese medicine prescriptions published in the fifth edition are as follows:

[0088] 1. Medical observation period: Huoxiang Zhengqi Capsules (water, oral liquid) or Jinhua Qingre Granules are used.

[0089] 2. Clinical treatment period: (1) the initial period prescription: Atractylodes lancea 15 g, Dried Orange Peel 10 g, Magnolia officinalis 10 g, Agastache rugosa 10 g, Lanxangia tsao-ko 6 g, raw Chinese ephedra 6 g, Notopterygium incisum 10 g, Ginger 10 g, Areca catechu 10 g.

[0090] (2) The medium period prescription: Almond 10 g, Gypsum 30 g, Trichosanthes kiriiowii 30 g, raw Rheum officinale 6 g (decocted later), raw Chinese ephedra 6 g, Semen Lepidii 10 g, Peach Kernel 10 g, Lanxangia tsao-ko 6 g, Areca catechu 10 g and Atractylodes lancea 10 g.

[0091] (3) The severe period prescription: Ginseng 15 g, black prepared lateral root of aconite (Aconitum camiichaeli) 10 g, Cornus officinalis 15 g.

[0092] 3. The prescription in the recovery period: Rhizoma pineliae praeparata 9 g, Dried Orange Peel 10 g, Codonopsis pilosula 10 g, Astragalus membranaceus 30 g, Poria cocos 15 g, Agastache rugosa 10 g, Amomum villosum (decocted later) 6 g,

[0093] According to the analysis of the four compositions, the drugs mainly used are dampness resolving drugs, antiasthmatic drugs, phlegm resolving drugs, etc., so they are effective for mild- or medium-period patients, but not for severe-period patients. Their main disadvantage is the lack of drugs that can pass through the blood-brain barrier. The medicine provided by the invention is added with drugs such as Gastrodia data, Uncaria rhynchophylla and Rhizoma arisaematis that can pass through blood-brain barrier, so the technical effect will be significantly improved compared to that of the above-mentioned compositions. Because the symptoms of “oxygen lack with coma” are obvious symptoms of brain infections, and viruses or fungi often easily invade the brain tissues, the development of the disease can't be controlled in the middle and late periods without the treatment of the brain infections. Moreover, the medicine provided by the invention is manufactured by extracting alkaloids and/or volatile oils from various plants, and the chemical ingredients are clear. Compared to traditional Chinese medicine decoctions, the technical effect of the medicine of the invention is obvious.

Example 3

[0094] The example is a medicine for treating infectious diseases caused by Cryptococcus or AIDS.

[0095] 1. The first clinical symptoms are the symptoms of upper respiratory tract infections such as chills, fever, headache, dizziness, sore throat, conjunctivitis, nasal congestion, nausea, vomiting, general discomfort and other symptoms.

[0096] The composition of the active pharmaceutical ingredients (dry product) of this example is as follows: total alkaloids and/or volatile oils extracted from 30 g of Gastrodia elata, total alkaloids and/or volatile oils extracted from 30 g of Pinellia ternata, total alkaloids and/or volatile oils extracted from 25 g of Orange Peel, total alkaloids and/or volatile oils extracted from 30 g of Uncaria rhynchophylla, total alkaloids and/or volatile oils extracted from 15 g of Ginger, total alkaloids and/or volatile oils extracted from 10 g of Notopterygium incisum, total alkaloids and/or volatile oils extracted from 15 g of Ligusticum wallichii, total alkaloids and/or volatile oils extracted from 20 g of Mentha haplocalyx, total alkaloids and/or volatile oils extracted from 20 g of Chaste Tree Fruits, total alkaloids and/or volatile oils extracted from 15 g of Ligusticum wallichii, and total alkaloids and/or volatile oils extracted from 20 g of Atractylodes lancea.

[0097] 2. When the patient's condition develops to severe eye symptoms or mental symptoms or central nervous system injury or general symptoms, the composition of the active pharmaceutical ingredients (dry product) of this example is as follows: total alkaloids and/or volatile oils extracted from 50 g of Gastrodia elata, total alkaloids and/or volatile oils extracted from 30 g of Pinellia ternata, total alkaloids and/or volatile oils extracted from 25 g of. Orange Peel, total alkaloids and/or volatile oils extracted from 50 g of Uncaria rhynchophylla, total alkaloids and/or volatile oils extracted from 30 g of Rhizoma arisaematis, total alkaloids and/or volatile oils extracted from 20 g of Aconitum carmichaeli, total alkaloids and/or volatile oils extracted from 25 g of Ligusticum wallichii, total alkaloids and/or volatile oils extracted from 25 g of Ginger, total alkaloids and/or volatile oils extracted from 15 g of Notopterygium incisum, total alkaloids and/or volatile oils extracted from 20 g of Radix angelicae pubescentis, total alkaloids and/or volatile oils extracted from 20 g of Achyranthes bidentata, and total alkaloids and/or volatile oils extracted from 20 g of Atractylodes lancea.

Example 4

[0098] The example is a medicine for treating infectious diseases caused by Mucor or Entomophthora or Ebola, virus. The clinical symptoms are headache, nasal discharge stained with blood, eye congestion, tumor of one side of the face, nerve palsy, chest tightness, chest pain, cough and bloody sputum. The onset of the disease is acute, it can progress to systemic hemorrhage soon, and can cause death within 2 weeks.

[0099] The composition of the active pharmaceutical ingredients (dry product) of this example is as follows: total alkaloids and/or volatile oils extracted from 50 g of Gastrodia elata, total alkaloids and/or volatile oils extracted from 50 g of Pinellia ternata, total alkaloids and/or volatile oils extracted from 50 g of Orange Peel, total alkaloids and/or volatile oils extracted from 50 g of Uncaria rhynchophylla, total alkaloids and/or volatile oils extracted from 50 g of Rhizoma arisaematis, total alkaloids and/or volatile oils extracted from 50 g of Aconitum carmichaeli, total alkaloids and/or volatile oils extracted from 50 grams of Astragalus membranaceus, total alkaloids and/or volatile oils extracted from 50 g of Cirsium setosum, and total alkaloids and/or volatile oils extracted from 50 g of Cirsium japonicum.

[0100] Of course, the examples above are only for the purpose of clearly illustrating the examples given, rather than limiting the implementation mode. Based upon the above description, other different changes or modifications can be also made by those skilled in the art. It is unnecessary and impossible to enumerate all the examples here, and the obvious changes or variations thus extended are still within the protection scope of the present invention.

Preparation Methods

[0101] The preparation method 1 is as follows: according to the weight parts of the selected raw materials in the above examples, alkaloids and volatile oils are extracted from each of the raw materials using modern conventional extraction methods; the alkaloids are mixed, and added with conventional excipients; pharmaceutically acceptable dosage forms such as tablets or powder injections are prepared according to conventional processes for preparing medicines.

[0102] Then, the volatile oils are mixed, and added with conventional excipients; pharmaceutically acceptable dosage forms such as soft capsules or granules and topical liniments are prepared according to conventional processes for preparing medicines.

[0103] The volatile oils are mixed in a proportion and then mixed with the dry alkaloid substances and an appropriate amount of excipients after inclusion with beta-cyclodextrin; pharmaceutically acceptable dosage forms such as tablets, granules are prepared using conventional methods for preparing medicines.

[0104] The preparation method 2 is as follows: according to the weight parts of the selected raw materials in the above examples, alkaloids contained in Gastrodia elata, Pinellia ternata, Orange Peel and Uncaria rhynchophylla are extracted using conventional methods and added with conventional excipients, and pharmaceutically acceptable dosage forms such as tablets or powder injections are prepared according to conventional processes for preparing medicines; then, alkaloids extracted from additional raw materials are mixed, and added with conventional excipients; pharmaceutically acceptable dosage forms such as tablets or powder injections are prepared according to conventional processes for preparing medicines, and an A+B combination is obtained.

[0105] Then, volatile oils extracted from Gastrodia elata, Pinellia temata, Orange Peel and Uncaria rhynchophylla are mixed, and added with conventional excipients; pharmaceutically acceptable dosage forms such as soft capsules or granules are prepared according to conventional processes for preparing medicines; then, volatile oils extracted from additional raw materials are mixed, and added with conventional excipients; pharmaceutically acceptable dosage forms such as soft capsules or granules are prepared according to conventional processes for preparing medicines, and an A+B combination is obtained.

[0106] Alternatively, volatile oils extracted from Gastrodia elata, Pinellia ternata, Orange Peel and Uncaria rhynchophylla are mixed in a proportion and then mixed with the dry alkaloid substances and an appropriate amount of excipients after inclusion with beta-cyclodextrin; pharmaceutically acceptable dosage forms such as tablets, granules are prepared using conventional methods for preparing medicines; then, volatile oils extracted from additional raw materials are mixed in a proportion and then mixed with the dry alkaloid substances and an appropriate amount of excipients after inclusion with beta-cyclodextrin; pharmaceutically acceptable dosage forms such as tablets, granules are prepared using conventional methods for preparing medicines, and an A+B combination is obtained.

[0107] The preparation method 3 is as follows: total alkaloids and/or total volatile oils are extracted from corresponding fresh raw materials and then grouped to prepare medicine, wherein a standard dose of 15 g of the dry product is used for each of the raw materials. The alkaloids in each of the groups are mixed, and added with conventional excipients; pharmaceutically acceptable dosage forms such as tablets or powder injections are prepared according to conventional processes for preparing medicines.

[0108] Then, the volatile oils in each of the groups are mixed, and added with conventional excipients; pharmaceutically acceptable dosage forms such as soft capsules or granules and topical liniments are prepared according to conventional processes for preparing medicines.

[0109] Furthermore, the volatile oils in each of the groups are mixed in a proportion and then mixed with the dry alkaloid substances and an appropriate amount of excipients after inclusion with beta-cyclodextrin; pharmaceutically acceptable dosage forms such as tablets, granules are prepared using conventional methods for preparing medicines. The specific grouping is as follows:

[0110] The first group: total alkaloids and/or volatile oils extracted from 15 g of Gastrodia elata, total alkaloids and/or volatile oils extracted from 15 g of Pinellia ternata, total alkaloids and/or volatile oils extracted from 15 g of Orange Peel, total alkaloids and/or volatile oils extracted from 15 g of Uncaria rhynchophylla.

[0111] The second group: total alkaloids and/or volatile oils extracted from 15 g of Ginger, total alkaloids and/or volatile oils extracted from 15 g of Notopterygium incisum, total alkaloids and/or volatile oils extracted from 15 g of Saposhnikovia divaricata, total alkaloids and/or volatile oils extracted from 15 g of Ligusticum levisticum, total alkaloids and/or volatile oils extracted from 15 g of Flos Magnoliae.

[0112] The third group: total alkaloids and/or volatile oils extracted from 15 g of Mentha haplocalyx, total alkaloids and/or volatile oils extracted from 15 g of Mulberry Leaves, total alkaloids and/or volatile oils extracted from 15 g of Chaste Tree Fruits.

[0113] The fourth group: total alkaloids and/or volatile oils extracted from 15 g of Agastache rugosa, total alkaloids and/or volatile oils extracted from 15 g of Atractylodes lancea, total alkaloids and/or volatile oils extracted from 15 g of Magnolia officinalis, total alkaloids and/or volatile oils extracted from 15 g of Garlic.

[0114] The fifth group: total alkaloids and/or volatile oils extracted from 15 g of Rhizoma. arisaematis, total alkaloids and/or volatile oils extracted from 15 g of Sinapis alba, total alkaloids and/or volatile oils extracted from 15 g of Radix Stemona.

[0115] The sixth group: total alkaloids and/or volatile oils extracted from 15 g of Fritillaria cirrhosa, total alkaloids and/or volatile oils extracted from 15 g of Trichosanthes kirilowii, total alkaloids and/or volatile oils extracted from 15 g of Semen Lepidii.

[0116] The seventh group: total alkaloids and/or volatile oils extracted from 15 g of Radix angelicae pubescentis, total alkaloids and/or volatile oils extracted from 15 g of Achyranthes bidentata, total alkaloids and/or volatile oils extracted from 15 g of Aconitum carmichaeli, total alkaloids and/or volatile oils extracted from 15 g of Herba artemisiae scopariae.

[0117] The eighth group: total alkaloids and/or volatile oils extracted from 15 g of Astragalus membranaceus, total alkaloids and/or volatile oils extracted from 15 g of Angelica sinensis, total alkaloids and/or volatile oils extracted from 15 g of Ligusticum wallichii.

[0118] The ninth group: total alkaloids and/or volatile oils extracted from 15 g of Cirsium setosum, total alkaloids and/or volatile oils extracted from 15 g of Cirsium japonicum.

Technical Effect

[0119] The traditional prescriptions such as the “Banxia Baizhu Tianma Decoction”, “Er Chen Decoction” and “Yu Hu Pill”, as well as other plant medicines have been clinically proved to be safe and effective. The medicine provided by the invention is based on raw materials of traditional medicine prescriptions, wherein total alkaloids and/or volatile oils contained in plants such as Gastrodia elata, Pinellia ternata, Orange Peel, Unearia rhynchophylla are extracted to prepare medicines or health products for treating influenza or infectious diseases. Since the chemical ingredients of a medicine or health product provided by the invention are definite, their pharmacological action is clear, and the effectiveness thereof is obvious and predictable when comparing traditional methods for preparing drugs with the methods for preparing modern Chinese patent medicines.

[0120] During the treatment of pneumonia caused by novel coronavirus in 2020, it was proved that traditional decoctions can have a better therapeutic effect on patients with mild symptoms. It was reported at a news conference in China that chloroquine phosphate had a certain diagnosis and treatment effect on the new coronavirus. Chloroquine phosphate is phosphate of chloroquine, and chloroquine is derived from the structural optimization of quinine, wherein quinine is an alkaloid extracted from a plant such as Cinchona. It is proved that alkaloids have an effect against novel coronavirus.

[0121] Because the applicant has no conditions to extract alkaloids and/or volatile oils from the raw materials for clinical trials, but those skilled in the art are able to implement the technical solution of the invention based on the contents recorded in this description and the common technical knowledge in the art to solve the technical problems and provide the expected technical effect.

[0122] The inventive step of the medicine provided by the invention is as follows: the active pharmaceutical ingredients are total alkaloids and/or volatile oils extracted from Gastrodia elata, total alkaloids and/or volatile oils extracted from Pinellia ternata, total alkaloids and/or volatile oils extracted from Orange Peel, total alkaloids and/or volatile oils extracted from Uncaria rhynchophylla, etc. It is clear that the chemical ingredients of each of the raw materials are alkaloids and volatile oils. Compared with the existing pharmaceutical chemicals which are medicines made from alkaloids extracted from a single plant, the medicine provided by the invention can reduce the content of a single alkaloid in a medicine, reduce the toxic reaction caused by the excessive dosage of the single alkaloid, and improve the drug tolerability. Moreover, the medicines provided by the invention can have a more effective targeting action on viral or fungal infections in different parts due to the synergistic effect of multiple alkaloids, and has more drug resistance. Because the inventor thinks that the immunity of human body comes from the resistance to Candida albicans in the body, and the medicine provided by the invention acts against Candida albicans, so the medicine provided by the invention also has immunosuppressive action.

[0123] Furthermore, compared with traditional Chinese medicines prepared using modern methods for preparing drugs, the medicines provided by the present invention show significant progress. Because not all Chinese medicines are necessarily obtained from herbs, but also from animals and minerals, the most important feature of modern Chinese medicines is that it is possible to know only the main ingredients, rather than to know all the ingredients, and the pharmacological mechanism of the existing Chinese patent medicines is not clear; and the chemical ingredients of the medicine provided by the invention are only alkaloids and volatile oils, so the chemical ingredients are definite. The pharmacological mechanism of the medicine provided by the invention is clear, wherein its pharmacological mechanism is that the total alkaloids of each of the raw materials have antifungal and antiviral effects, as well as the total volatile oils of each of the raw materials have antifungal and antiviral effects. Moreover, these alkaloids and volatile oils have their own characteristics, and can specifically target fungal or viral infections in different blood vessels, tissues and cells.

[0124] Therefore, the medicine provided by the invention has clear pharmacological mechanism and definite chemical ingredients. Compared with the medicines of modern Western medicine that are made of a single alkaloid, it is characterized by obvious curative effect, as well as by anti-drug resistance and weaker toxic side reactions. Compared with traditional Chinese medicines and modern Chinese patent medicines, the invention shows significant progress. The technical solution provided by the invention uses the advantages of drug combination therapy of traditional Chinese medicine, as well as the advantages of modern pharmaceutical chemicals, overcomes the shortcoming that the effective chemical ingredients and pharmacological mechanism of traditional Chinese medicine prescriptions are not clear, and also overcomes the disadvantages of modern Western medicine that the chemical ingredient is single, thereby easily causing side effects, toxic reactions and drug resistance.